WOODBRIDGE, ON, May 6, 2014 /PRNewswire/ - Pivotal
Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty
pharmaceutical company with a focus on Omega-3 therapies for
cardiovascular disease (CVD) and overall health, is pleased to
announce that it presented two posters at the American Heart
Association's Arteriosclerosis, Thrombosis and Vascular Biology
(ATVB) 2014 Scientific Sessions held in Toronto, Ontario, Canada, May 1-3, 2014. Both posters discussed Omega-3
deficiency (OM3D) and VASCAZEN®'s unique
formulation to correct the deficiency.
The first poster entitled "Correlation Between the Whole
Blood Omega-Score®, and Red Blood Cell
Membrane Omega-3 Index in a Patient Population with Cardiovascular
Disease Risk Factors, Treated with VASCAZEN®
a Unique Omega-3 Formulation" was presented on Friday, May 2, 2014. Omega-3 deficiency is
commonly evaluated by using two commercially available blood tests,
the Omega-Score® and Omega-3 Index that measure whole blood or red
blood cell membrane Omega-3 levels respectively. As evidenced by
this study, the Omega-Score® and Omega-3 Index give highly similar
comparative results and can be used interchangeably to evaluate
OM3D.
"The high degree of correlation between the
Omega-Score® and Omega-3 Index allows healthcare
practitioners to use either reimbursable test when testing for
OM3D. The identification and the correction of an OM3D is an
important part of managing a cardiac patients disease and may
assist with patient compliance," stated Dr. George Jackowski, Chief Scientific Officer. "We
are very excited with these results as we are in the process of
developing a rapid format point of care test (POCT) for
measuring blood levels of Omega-3's for the physicians office,"
added Dr. George Jackowski, Chief
Scientific Officer.
The second poster entitled "Correction of Long Chain Omega-3 Fatty Acids Deficiency with a
unique Omega-3 Formulation is Associated with a Significant
Reduction in Atherogenic Index of Plasma in Hypertriglyceridemic
Patients: Results from the VASCAZEN®-REVEAL
Trial" was presented on Saturday, May 3rd, 2014.
Atherogenicity index of plasma (AIP) is an emerging risk predictor
for cardiovascular disease. The poster demonstrated that a
correction of an Omega-3 deficiency in patients with
hypertriglyceridemia (200-500 mg/dl) resulted in a significant
decrease in AIP (-45%) within eight weeks of treatment with
VASCAZEN®.
"The second presentation is a follow-up analysis of the
VASCAZEN®-REVEAL Trial and illustrates that
correcting an OM3D with VASCAZEN® has multiple
benefits in cardiovascular patients, from helping support
circulation, to promoting proper inflammatory responses in the
body, and helping support normal triglyceride levels" said Dr.
Jackowski, Chief Scientific Officer.
About VASCAZEN®
VASCAZEN® is currently available in the U.S.
as a prescription only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular
patients. VASCAZEN® is a >90% pure Omega-3
with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by
a series of both U.S. and foreign patents.
VASCAZEN® has been clinically shown to correct
an Omega-3 deficiency within eight weeks of treatment with positive
concomitant effects on the lipid profiles, mainly a 48% reduction
of triglycerides and an increase of HDL without negative impact on
the LDL-C lipid profile. VASCAZEN®'s
results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE:
PVO) specialty pharmaceutical company with a focus on
cardiovascular disease and overall health. Pivotal Therapeutics'
lead product VASCAZEN® is a prescription only
Medical Food formulated to meet the dietary Omega-3 deficient needs
of patients with cardiovascular disease through elevating
Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular
complications. OMAZEN® is a pharmaceutical grade
Omega-3 providing over 90% pure Omega-3 in each capsule for the
maintenance of good health. OMAZEN® is a patented
product available for sale and distribution in Canada.
Disclosure Notice
The information contained in this
document is as of May 6, 2014. This
press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual
results to differ materially from those projected in such
forward-looking statements. These statements can be identified by
the use of words such as "will", "anticipate", "estimate",
"expect", "project", "forecast", "intend", "plan", "believe",
"project", "potential", and similar expressions with any discussion
of future operating or financial performance or events. In
particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to
compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance;
risks relating to the Company's ability to maintain its CSE
listing. Forward-looking statements speak only as of the date made
and are not guarantees of future performance. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements contained in this document as a result
of new information or future events or developments. CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this information.
SOURCE Pivotal Therapeutics Inc.